<p>/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (納斯達克代碼：ELOX)（&#34;Eloxx&#34;和&#34;公司&#34;），是一家臨牀階段的生物製藥公司，開發旨在調節核糖體並促進由於無義突變引起的早期終止密碼子的讀通過的創新小分子產品候選藥物，以實現全長蛋白質的生產。今天宣佈以每股 11.00 美元的公開發行價格，公開發行 2,975,000 股普通股，並以每個預先融資認購權證 10.99 美元的公開發行價格，發行最多 3,025,000 股普通股的預先融資認購權證，後者等於普通股每股的公開發行價格減去每個預先融資認購權證的 0.01 美元行使價格。所有將在此次發行中出售的證券均由 Eloxx 提供。Eloxx 預計在扣除承銷折扣和佣金及 Eloxx 應支付的發行費用之前，將獲得 6600 萬美元的毛收益。普通股預計將於 2026 年 6 月 9 日在納斯達克資本市場開始交易，交易代碼為&#34;ELOX&#34;。此次發行預計將於 2026 年 6 月 10 日完成，前提是滿足慣例的交割條件。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg"/></p>
<p>Leerink Partners 和 Guggenheim Securities 擔任此次發行的聯合賬簿管理人。LifeSci Capital 擔任此次發行的被動賬簿管理人。</p>
<p>與此次發行相關的 S-1 表格註冊聲明（文件編號：333-295651）已向證券交易委員會（&#34;SEC&#34;）提交，並於 2026 年 6 月 8 日生效。此次擬議的發行僅通過招股説明書進行。有關此次發行的最終招股説明書的副本可從以下地址獲得：Leerink Partners LLC，承銷部，53 State Street，40 樓，波士頓，MA 02109，或撥打電話（800）808-7525 分機 6105，或通過電子郵件聯繫 syndicate@leerink.com；以及 Guggenheim Securities, LLC，注意：股票承銷部，330 Madison Avenue，紐約，NY 10017，電話（212）518-9544，或通過電子郵件聯繫 GSEquityProspectusDelivery@guggenheimpartners.com。</p>
<p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下，進行此類要約、徵求或銷售將是非法的，除非已註冊或獲得資格。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明。除歷史事實外，本新聞稿中包含的所有聲明，包括但不限於關於預計發行收益、普通股在納斯達克資本市場的預期交易日期以及預計發行完成時間的聲明均為前瞻性聲明。前瞻性聲明可以通過&#34;目標&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;會&#34;、&#34;應該&#34;、&#34;期望&#34;、&#34;探索&#34;、&#34;計劃&#34;、&#34;預期&#34;、&#34;可以&#34;、&#34;打算&#34;、&#34;目標&#34;、&#34;項目&#34;、&#34;考慮&#34;、&#34;相信&#34;、&#34;估計&#34;、&#34;預測&#34;、&#34;潛在&#34;、&#34;尋求&#34;或&#34;繼續&#34;等詞語或這些詞語的否定形式來識別，儘管並非所有前瞻性聲明都包含這些詞。前瞻性聲明基於管理層當前的計劃、估計、假設和基於公司當前可用信息的預測。前瞻性聲明受到已知和未知的風險、不確定性和假設的影響，實際結果或結果可能因各種重要因素而與前瞻性聲明中表達或暗示的結果有重大不同，包括但不限於市場條件和在公司於 2026 年 6 月 4 日提交的 S-1 表格註冊聲明中討論的其他重要因素下的&#34;風險因素&#34;。</p>
<p>所有前瞻性聲明僅在本新聞稿日期有效，除非適用法律要求，公司沒有義務更新或修訂本聲明中包含的任何前瞻性聲明，無論是由於新信息、未來事件、情況變化或其他原因。</p>
<p><strong>聯繫方式：</strong> Eloxx Pharmaceuticals 投資者關係</p>
<p>ir@eloxxpharma.com</p>
<p>(781) 577-5300</p>
<p>來源：Eloxx Pharmaceuticals, Inc.</p>

ELOX

<p>Eloxx Pharmaceuticals 宣佈了一項 6600 萬美元的公開發行定價，出售 2,975,000 股普通股，價格為 11.00 美元，並預售最多 3,025,000 股的預付認股權證，價格為 10.99 美元。公司預計在扣除費用前的毛收入為 6600 萬美元。預計在 2026 年 6 月 9 日開始在納斯達克交易，預計在 2026 年 6 月 10 日完成交易。Leerink Partners 和 Guggenheim Securities 是聯合主承銷商</p>

<p>, /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) (&#34;Eloxx&#34; and the &#34;Company&#34;), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. All of the securities to be sold in the offering are being offered by Eloxx. Eloxx expects to receive gross proceeds of $66.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Eloxx. The shares of common stock are expected to begin trading on the Nasdaq Capital Market on June 9, 2026, under the symbol &#34;ELOX&#34;. The offering is expected to close on June 10, 2026, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (納斯達克代碼：ELOX)（&#34;Eloxx&#34;和&#34;公司&#34;），是一家臨牀階段的生物製藥公司，開發旨在調節核糖體並促進由於無義突變引起的早期終止密碼子的讀通過的創新小分子產品候選藥物，以實現全長蛋白質的生產。今天宣佈以每股 11.00 美元的公開發行價格，公開發行 2,975,000 股普通股，並以每個預先融資認購權證 10.99 美元的公開發行價格，發行最多 3,025,000 股普通股的預先融資認購權證，後者等於普通股每股的公開發行價格減去每個預先融資認購權證的 0.01 美元行使價格。所有將在此次發行中出售的證券均由 Eloxx 提供。Eloxx 預計在扣除承銷折扣和佣金及 Eloxx 應支付的發行費用之前，將獲得 6600 萬美元的毛收益。普通股預計將於 2026 年 6 月 9 日在納斯達克資本市場開始交易，交易代碼為&#34;ELOX&#34;。此次發行預計將於 2026 年 6 月 10 日完成，前提是滿足慣例的交割條件。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2996078/Eloxx_Pharmaceuticals_Logo.jpg"/></p>
<p>Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.</p>
<div class="lb-trans"><p>Leerink Partners 和 Guggenheim Securities 擔任此次發行的聯合賬簿管理人。LifeSci Capital 擔任此次發行的被動賬簿管理人。</p>
</div><p>A registration statement on Form S-1 (File No. 333-295651) relating to the offering has been filed with the Securities and Exchange Commission (the &#34;SEC&#34;) and became effective on June 8, 2026. The proposed offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</p>
<div class="lb-trans"><p>與此次發行相關的 S-1 表格註冊聲明（文件編號：333-295651）已向證券交易委員會（&#34;SEC&#34;）提交，並於 2026 年 6 月 8 日生效。此次擬議的發行僅通過招股説明書進行。有關此次發行的最終招股説明書的副本可從以下地址獲得：Leerink Partners LLC，承銷部，53 State Street，40 樓，波士頓，MA 02109，或撥打電話（800）808-7525 分機 6105，或通過電子郵件聯繫 syndicate@leerink.com；以及 Guggenheim Securities, LLC，注意：股票承銷部，330 Madison Avenue，紐約，NY 10017，電話（212）518-9544，或通過電子郵件聯繫 GSEquityProspectusDelivery@guggenheimpartners.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下，進行此類要約、徵求或銷售將是非法的，除非已註冊或獲得資格。</p>
</div><p><strong>Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including without limitation, statements regarding the anticipated proceeds from the offering, the expected trading date for the shares of common stock on the Nasdaq Capital Market and the anticipated timing of closing of the offering are forward-looking statements. Forward-looking statements can be identified by the words &#34;aim,&#34; &#34;may,&#34; &#34;will,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;explore,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;contemplate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;predict,&#34; &#34;potential,&#34; &#34;seeks,&#34; or &#34;continue&#34; or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to the Company. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to market conditions and other important factors discussed under the caption &#34;Risk Factors&#34; in the Company's Registration Statement on Form S-1 filed on June 4, 2026.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明。除歷史事實外，本新聞稿中包含的所有聲明，包括但不限於關於預計發行收益、普通股在納斯達克資本市場的預期交易日期以及預計發行完成時間的聲明均為前瞻性聲明。前瞻性聲明可以通過&#34;目標&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;會&#34;、&#34;應該&#34;、&#34;期望&#34;、&#34;探索&#34;、&#34;計劃&#34;、&#34;預期&#34;、&#34;可以&#34;、&#34;打算&#34;、&#34;目標&#34;、&#34;項目&#34;、&#34;考慮&#34;、&#34;相信&#34;、&#34;估計&#34;、&#34;預測&#34;、&#34;潛在&#34;、&#34;尋求&#34;或&#34;繼續&#34;等詞語或這些詞語的否定形式來識別，儘管並非所有前瞻性聲明都包含這些詞。前瞻性聲明基於管理層當前的計劃、估計、假設和基於公司當前可用信息的預測。前瞻性聲明受到已知和未知的風險、不確定性和假設的影響，實際結果或結果可能因各種重要因素而與前瞻性聲明中表達或暗示的結果有重大不同，包括但不限於市場條件和在公司於 2026 年 6 月 4 日提交的 S-1 表格註冊聲明中討論的其他重要因素下的&#34;風險因素&#34;。</p>
</div><p>All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<div class="lb-trans"><p>所有前瞻性聲明僅在本新聞稿日期有效，除非適用法律要求，公司沒有義務更新或修訂本聲明中包含的任何前瞻性聲明，無論是由於新信息、未來事件、情況變化或其他原因。</p>
</div><p><strong>Contact:</strong> Eloxx Pharmaceuticals Investor Relations</p>
<div class="lb-trans"><p><strong>聯繫方式：</strong> Eloxx Pharmaceuticals 投資者關係</p>
</div><p>ir@eloxxpharma.com</p>
<div class="lb-trans"><p>ir@eloxxpharma.com</p>
</div><p>(781) 577-5300</p>
<div class="lb-trans"><p>(781) 577-5300</p>
</div><p>SOURCE Eloxx Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>來源：Eloxx Pharmaceuticals, Inc.</p>
</div>

Eloxx Pharmaceuticals, Inc. 宣佈 6600 萬美元公開發行的定價及在納斯達克上市 | ELOX 股票新聞